Clinical Trial Update: This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of ZM008, an anti-LLT1 antibody, given as a single agent and then in combination with toripalimab in patients with advanced solid tumors;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Adenocarcinoma
• Prostate Cancer
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)
• ZM008

Snippet

Sponsor: Zumutor Biologics Inc. | Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: RECRUITING